Latest News
The AIM-quoted investment group China Private Equity Investments Holdings Limited (CPE) has agreed to develop a strategic partnership with Hong Kong-based Gen2 Capital Partners Limited, an independent asset management firm with assets under management of approximately USD500million.
The move is intended to boost CPE’s growth potential by marrying its own private equity experience with Gen2’s proven investment and risk management processes in the Greater China region.
As part of the agreement, CPE intends to appoint David Kiang, a Gen2 senior advisor, to the CPE Board as a Non-Executive Director.
CPE has already reviewed the current portfolio of assets
Ingenious Investments, part of UK-based investment and advisory group Ingenious, has launched the African Solar Fund, a social impact investment fund which aims to transform the energy supply for some of the most economically deprived households in Africa.
Social impact investment is a rapidly developing asset class that enables investors to make investments that generate financial returns while simultaneously having positive social, and often environmental, benefits.
The fund will invest in one or more companies which distribute innovative “off-grid” solar technology, such as solar panels which power LED lamps and mobile phone charging cables, to households in rural African
Hancocks Group, which includes Hancocks Cash and Carry, has been sold to its management and H2 Equity Partners.
The new ownership sees both Andrew and Adrian Hancock step back from the company.
Established in 1962 by Andrew and Adrian’s father Ray Hancock, the Hancocks Group has been owned and managed by the family for 50 years. In that time it has grown to a business with over GBP100m in sales.
H2 Equity Partners plans to build on Hancocks’ strong position in the market to take the company forward in the coming years. H2 and management will work together
The AIM-quoted investment group China Private Equity Investments (CPE) has agreed to develop a strategic partnership with Hong Kong-based asset management firm Gen2 Capital Partners.
The move is intended to boost CPE’s growth potential by marrying its own private equity experience with Gen2’s investment and risk management processes in the Greater China region.
As part of the agreement, CPE intends to appoint David Kiang, a Gen2 senior adviser, to the CPE board as a non-executive director.
CPE has already reviewed the current portfolio of assets held by Gen2, and identified a number of assets that would be attractive additions to
Ben Eaton has joined Goodwin Procter as a partner in the firm’s London office.
Eaton (pictured) comes to Goodwin from Allen & Overy in London.
As a member of the firm’s tax practice, Eaton’s initial focus will be on tax matters involving investment funds and real estate transactions.
He has considerable experience advising on the tax aspects of numerous types of funds, including private equity, infrastructure/renewables, debt, hedge and real estate. In addition to his multi-sector expertise in the fund formation area, he has advised clients on all aspects of real estate work, including investment, financing, development and leasing as
Doug Lawson has joined Lazard Middle Market as a managing director and head of packaging within its industrials group.
He is based in Chicago.
“Doug has established a national reputation in the packaging sector, having advised on many of the most notable middle market transactions in the sector in recent years,” says Bob Frost, head of the industrial group for Lazard Middle Market.
Lawson’s investment banking experience include numerous sale and buy-side advisory mandates, leveraged buyouts, and fairness opinions for a wide variety of clients, including private equity groups, public companies, and privately owned businesses.
Prior to joining Lazard, Lawson
Silverfleet Capital, the European private equity firm, has promoted three of its investment team.
Mark Piasecki, who is based in London, has been promoted to principal.
Robert Knight, also based in London, and Cyril Bourdarot who is based in Paris, have become investment executives.
Neil MacDougall (pictured), managing partner of Silverfleet Capital, says: “Mark, Cyril and Robert have all made very significant contributions to our firm and the partners at Silverfleet Capital have recognised their hard work through these promotions.
“Silverfleet Capital has strong and experienced investment teams based in each of our London, Paris and Munich offices which enable
Apex Fund Services has expanded its private equity services following regulatory approval to open an office in Guernsey.
Apex’s fund managers, particularly in the LATAM, Middle East and Asian emerging markets, continue to demonstrate their growing demand for private equity fund structures.
Apex has begun providing its clients with the services they are calling for from Guernsey.
Over 40 per cent of all Guernsey closed ended funds are private equity and as a consequence the jurisdiction has developed some of the most specialist industry expertise in the world.
In addition, Apex has launched its open-ended Protected Cell Company
Michael Deleray has joined investment bank and growth equity investor Broadhaven Capital Partners as a partner.
Deleray has enjoyed a career in financial services as a senior executive, investor and strategic adviser, and will be a key participant in Broadhaven’s expanded coverage of the global financial services industry.
"We are extremely pleased to welcome Mike to Broadhaven, adding to our deep expertise across the financial services spectrum," says Greg Phillips, co-founder of Broadhaven. "Our clients and portfolio companies will immediately benefit from his experience as an executive and strategic advisor."
Deleray was previously a founder of Bendigo Partners, a private
Clinical stage biotechnology company MabVax Therapeutics has closed the first tranche in the company’s series B financing.
Numoda Capital Innovations led the round and was joined by existing investors Burrill Capital Fund IV and RTP Venture Fund for an aggregate investment of USD5.25m.
The additional capital will allow MabVax to continue the development of its phase 2 vaccine aimed at preventing recurrent sarcoma and its 5B1 antibody programme targeting metastatic pancreatic cancer.
The phase 2 clinical trial of the sarcoma vaccine has reached the targeted enrolment of 134 stage IV sarcoma patients in a random, multi-centre, double-blind study of a
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
